ALLERGY THERAPEUTICS PLC

Report Publication Announcement • Aug 15, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7270L

Allergy Therapeutics PLC

15 August 2013

15 August 2013

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of results and shareholder update

Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its Preliminary Results for the year ended 30 June 2013 on Monday 16 September 2013.

The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2013 on the 15 August 2013. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

Balance Sheet as at 31 March 2013

	£ '000
Total Non-Current Assets	13,837
Total Current Assets	18,198
Total Current Liabilities	(6,913)
Total Non-Current Liabilities	(5,493)
Total Equity	19,630

Consolidated Income Statement for the 6 months ended 31 March 2013

	£'000
Revenue	26,760
Profit after tax for the period	4,564

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2012.

-Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer Ian Postlethwaite Finance Director
Nomura Code Securities	+44 (0) 207 776 1200
Juliet Thompson/ Clare Terlouw

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPIMFTMBBBBJJ